Darzalex Hepatitis B Virus Reactivation Death
Health Canada Issues Warning Concerning HBV Reactivation with Fatal Outcome OTTAWA, Ontario, Canada — According to Health Canada, the agency in charge of ensuring the safety of medicines marketed in Canada in the same manner that the Food and Drug Administration does in the U.S., issued an alert on March 25, 2019 warning … [Read more...] about Darzalex Hepatitis B Virus Reactivation Death
Hepatitis B Virus Reactivation Deaths Linked to Daratumumab
Anti-Cancer Drug daratumumab Places People at Risk from Hepatitis B Virus Reactivation with Fatal Outcome OTTAWA, Ontario, Canada — Health officials in Canada with the agency Health Canada have issued a warning to oncologists and other physicians treating patients with multiple myeloma that taking daratumumab manufactured by … [Read more...] about Hepatitis B Virus Reactivation Deaths Linked to Daratumumab
Fatal Darzalex Hepatitis B Virus Reactivation Complications
DARALEX Suspected of Causing Hepatitis B Virus Reactivation in Cancer Patients with Fatal Outcome OTTAWA, Ontario, Canada — Health Canada warns cancer patients suffering from multiple myeloma are at an elevated risk of Hepatitis B virus reactivation while taking the anti-cancer drug DARZALEX. Janssen, Inc., the company that … [Read more...] about Fatal Darzalex Hepatitis B Virus Reactivation Complications
